Table 3.
Effect of Royal jelly on ovarian morphometric analysis and quantitation of folliculogenesis in cisplatin-treated female rats
|
Follicular Counts
|
||||||||
|---|---|---|---|---|---|---|---|---|
| SPAF | LPAF | SAF | MAF | LAF | GF | Corpus luteum | Atretic follicles | |
| Control | 26.40±1.4 | 20.50± 2.4 | 16.50± 1.2 | 12.8± 1.6 | 9.62± 2.2 | 7.2±1.4 | 3.8 ±1.2 | 2.8± 0.8 |
| Cisplatin | 3.12± 0.6a | 1.34±0.4a | 2±0.7 a | 2± 0.5a | 1± 0.3a | 1.1±0.2 a | 1±0.2 a | 10.17±0.9 a |
| RJ+Cis. | 25.1± 2b | 18.2±0.6 b | 14.1±0.6b | 11.2± 0.5 b | 8.1± 0.2 b | 5.1±0.3 b | 2±0.4b | 3.17± 0.6b |
Values were expressed as mean±SD. Cis. refers to cisplatin. (RJ): Royal jelly, (SPAF): Small preantral follicle, (LPAF): Large preantral follicle, (SAF): Small antral follicle, (MAF): Medium antral follicle, (LAF): Large antral follicle (LAF) and (GF) Graafian follicles
a: indicates a significant difference (P<0.05) when compared to the control group. b: indicates a significant difference (P<0.05) when compared to the cisplatin group